At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HCC Warrior Met Coal LLC
Market Closed 12-20 16:00:00 EST
54.93
-0.93
-1.66%
盘后54.93
+0.000.00%
16:36 EST
High56.01Low54.40Vol1.41M
Open54.64D1 Closing55.86Amplitude2.88%
Mkt Cap2.87BTradable Cap2.82BTotal Shares52.31M
T/O77.61MT/O Rate2.74%Tradable Shares51.38M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Barington nominates Mitarotonda and two others as directors at Matthews, sources say
Reuters  ·  12-19
Barington nominates Mitarotonda and two others as directors at Matthews, sources say
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
GlobeNewswire  ·  12-18
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
GlobeNewswire  ·  12-18
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
Business Wire  ·  12-16
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC
Business Wire  ·  12-16
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
GlobeNewswire  ·  12-12
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
Business Wire  ·  12-09
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
Analysts Offer Insights on Materials Companies: Warrior Met Coal (HCC) and GoldMining (GLDG)
TIPRANKS  ·  12-08
Analysts Offer Insights on Materials Companies: Warrior Met Coal (HCC) and GoldMining (GLDG)
IMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancer
Business Wire  ·  12-06
IMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancer
RBC Raises Price Target on Warrior Met Coal to $75 From $70, Keeps Sector Perform Rating
MT Newswires Live  ·  12-06
RBC Raises Price Target on Warrior Met Coal to $75 From $70, Keeps Sector Perform Rating
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
Business Wire  ·  12-05
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
GlobeNewswire  ·  12-04
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
GlobeNewswire  ·  12-03
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
GlobeNewswire  ·  12-03
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma
ACCESSWIRE  ·  12-02
Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma
ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion
Zacks  ·  11-28
ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion
Warrior Met Coal, Inc.'s (NYSE:HCC) Intrinsic Value Is Potentially 24% Below Its Share Price
Simply Wall St.  ·  11-27
Warrior Met Coal, Inc.'s (NYSE:HCC) Intrinsic Value Is Potentially 24% Below Its Share Price
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
Business Wire  ·  11-27
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
Zacks  ·  11-23
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ACCESSWIRE  ·  11-22
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Introduction

Company Name.
Warrior Met Coal LLC
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Warrior Met Coal, Inc. produces and exports non-thermal metallurgical coal for the steel industry. It operates two underground mines located in Alabama. The company sells its metallurgical coal to a customer base of blast furnace steel producers located primarily in Europe, South America, and Asia. It also sells natural gas, which is extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama.
Issue price:
--